Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2824) 2824
daunorubicin - administration & dosage (2395) 2395
male (1811) 1811
female (1735) 1735
science & technology (1720) 1720
life sciences & biomedicine (1660) 1660
antineoplastic combined chemotherapy protocols - therapeutic use (1471) 1471
cytarabine - administration & dosage (1449) 1449
adult (1253) 1253
middle aged (1211) 1211
biological and medical sciences (1070) 1070
medical sciences (1068) 1068
adolescent (946) 946
leukemia, myeloid, acute - drug therapy (843) 843
oncology (829) 829
aged (822) 822
remission induction (740) 740
hematology (731) 731
animals (708) 708
chemotherapy (706) 706
pharmacology. drug treatments (697) 697
vincristine - administration & dosage (658) 658
child (644) 644
antineoplastic agents (599) 599
daunorubicin - therapeutic use (573) 573
daunorubicin (558) 558
daunorubicin - adverse effects (482) 482
child, preschool (464) 464
treatment outcome (438) 438
antineoplastic combined chemotherapy protocols - adverse effects (426) 426
prednisone - administration & dosage (414) 414
acute disease (379) 379
prognosis (376) 376
cyclophosphamide - administration & dosage (369) 369
methotrexate - administration & dosage (363) 363
mice (351) 351
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (350) 350
daunorubicin - analogs & derivatives (341) 341
abridged index medicus (338) 338
asparaginase - administration & dosage (335) 335
time factors (334) 334
daunorubicin - pharmacology (330) 330
thioguanine - administration & dosage (330) 330
antineoplastic combined chemotherapy protocols - administration & dosage (327) 327
hematologic and hematopoietic diseases (327) 327
antibiotics, antineoplastic - administration & dosage (317) 317
mercaptopurine - administration & dosage (315) 315
drug administration schedule (312) 312
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (310) 310
infant (308) 308
etoposide - administration & dosage (307) 307
doxorubicin - administration & dosage (288) 288
prednisolone - administration & dosage (273) 273
cancer (269) 269
drug therapy, combination (268) 268
combined modality therapy (264) 264
antineoplastic agents - administration & dosage (261) 261
leukemia (257) 257
leukemia, myeloid, acute - mortality (257) 257
leukemia, myeloid - drug therapy (256) 256
disease-free survival (253) 253
pharmacology & pharmacy (252) 252
dose-response relationship, drug (241) 241
survival rate (239) 239
cytarabine - therapeutic use (235) 235
acute myeloid leukemia (233) 233
leukemia - drug therapy (221) 221
follow-up studies (218) 218
rats (216) 216
anthracyclines (212) 212
cytarabine - adverse effects (211) 211
survival analysis (197) 197
mitoxantrone - administration & dosage (189) 189
recurrence (187) 187
liposomes (178) 178
aged, 80 and over (176) 176
daunorubicin - pharmacokinetics (175) 175
daunorubicin - toxicity (175) 175
pediatrics (174) 174
clinical trials as topic (163) 163
idarubicin - administration & dosage (163) 163
retrospective studies (163) 163
antineoplastic agents - therapeutic use (160) 160
leukemia, myeloid, acute - pathology (158) 158
leukemia, lymphoid - drug therapy (153) 153
bone marrow transplantation (151) 151
daunorubicin - metabolism (146) 146
drug evaluation (144) 144
age factors (143) 143
prospective studies (141) 141
young adult (135) 135
antibiotics, antineoplastic - adverse effects (132) 132
bone marrow - pathology (131) 131
drug resistance (131) 131
leukemia, promyelocytic, acute - drug therapy (131) 131
antibiotics, antineoplastic - therapeutic use (130) 130
tumors (128) 128
research (126) 126
idarubicin (123) 123
injections, intravenous (119) 119
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3106) 3106
Japanese (176) 176
Russian (116) 116
German (70) 70
French (47) 47
Polish (40) 40
Spanish (33) 33
Chinese (32) 32
Italian (15) 15
Czech (7) 7
Danish (4) 4
Bulgarian (2) 2
Dutch (2) 2
Hebrew (2) 2
Hungarian (2) 2
Portuguese (2) 2
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)
by Rytting, Michael E and Thomas, Deborah A and O'Brien, Susan M and Ravandi-Kashani, Farhad and Jabbour, Elias J and Franklin, Anna R and Kadia, Tapan M and Pemmaraju, Naveen and Daver, Naval G and Ferrajoli, Alessandra and Garcia-Manero, Guillermo and Konopleva, Marina Y and Cortes, Jorge E and Borthakur, Gautham and Garris, Rebecca and Cardenas-Turanzas, Maria and Schroeder, Kurt and Jorgensen, Jeffrey L and Kornblau, Steven M and Kantarjian, Hagop M
Cancer, ISSN 0008-543X, 12/2014, Volume 120, Issue 23, pp. 3660 - 3668
Augmented Berlin-Frankfurt-Munster | Pediatric-based regimens | Acute lymphoblastic leukemia | Pediatric-based therapy | Philadelphia chromosome-negative ALL | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Induction Chemotherapy | Male | Consolidation Chemotherapy | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Female | Maintenance Chemotherapy | Daunorubicin - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Mercaptopurine - administration & dosage | Treatment Outcome | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Thioguanine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Cohort Studies | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
by Cortes, Jorge E and Goldberg, Stuart L and Feldman, Eric J and Rizzeri, David A and Hogge, Donna E and Larson, Melissa and Pigneux, Arnaud and Recher, Christian and Schiller, Gary and Warzocha, Krzysztof and Kantarjian, Hagop and Louie, Arthur C and Kolitz, Jonathan E
Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 234 - 242
Phase II | Chemotherapy Intervention | Acute Myeloid Leukemia | First Relapse | Acute myeloid leukemia | First relapse | Chemotherapy intervention | Life Sciences & Biomedicine | Oncology | Science & Technology | Recurrence | Mitoxantrone - administration & dosage | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Aminoglycosides - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Daunorubicin - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Amsacrine - administration & dosage | Vidarabine - analogs & derivatives | Remission Induction | Cytarabine - administration & dosage | Cladribine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Injections | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Vidarabine - administration & dosage | Liposomes | Salvage Therapy - methods | Chemotherapy | Usage | Health aspects | Patient outcomes | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
by Powell, Bayard L and Moser, Barry and Stock, Wendy and Gallagher, Robert E and Willman, Cheryl L and Stone, Richard M and Rowe, Jacob M and Coutre, Steven and Feusner, James H and Gregory, John and Couban, Stephen and Appelbaum, Frederick R and Tallman, Martin S and Larson, Richard A
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 19, pp. 3751 - 3757
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tretinoin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Mercaptopurine - administration & dosage | Male | Treatment Outcome | North America | Cytarabine - administration & dosage | Young Adult | Disease-Free Survival | Arsenicals - administration & dosage | Adolescent | Leukemia, Promyelocytic, Acute - mortality | Survival Analysis | Adult | Female | Methotrexate - administration & dosage | Aged | Daunorubicin - administration & dosage | Oxides - administration & dosage | Leukemia, Promyelocytic, Acute - drug therapy | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
by Löwenberg, Bob and Ossenkoppele, Gert J and van Putten, Wim and Schouten, Harry C and Graux, Carlos and Ferrant, Augustin and Sonneveld, Pieter and Maertens, Johan and Jongen-Lavrencic, Mojca and von Lilienfeld-Toal, Marie and Biemond, Bart J and Vellenga, Edo and Kooy, Marinus van Marwijk and Verdonck, Leo F and Beck, Joachim and Döhner, Hartmut and Gratwohl, Alois and Pabst, Thomas and Verhoef, Gregor and Swiss Grp Clinical Canc Res SAKK C and Dutch-Belgian Cooperative Trial Gr and German AML Study Grp AMLSG and Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and German AML Study Group (AMLSG) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
The New England journal of medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 13, pp. 1235 - 1248
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Myelomonocytic, Acute - drug therapy | Stem Cell Transplantation | Antibodies, Monoclonal, Humanized | Leukemia, Myelomonocytic, Acute - therapy | Aminoglycosides - administration & dosage | Aged, 80 and over | Female | Remission Induction - methods | Daunorubicin - administration & dosage | Proportional Hazards Models | Combined Modality Therapy | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antibodies, Monoclonal - administration & dosage | Survival Analysis | Aged | Infusions, Intravenous | Leukemia, Myelomonocytic, Acute - mortality | Aged patients | Usage | Dosage and administration | Daunorubicin | Health aspects | Medical treatment | Leukemia | Age | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials
by Ramanujachar, Ramya and Richards, Sue and Hann, Ian and Goldstone, Anthony and Mitchell, Christopher and Vora, Ajay and Rowe, Jacob and Webb, David
Pediatric blood & cancer, ISSN 1545-5009, 03/2007, Volume 48, Issue 3, pp. 254 - 261
adolescent | young adult | acute lymphoblastic leukemia | treatment outcome | survival | Treatment outcome | Acute lymphoblastic leukemia | Survival | Adolescent | Young adult | Pediatrics | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Prognosis | Age Factors | Humans | Male | Transplantation, Autologous | Transplantation, Homologous | Patient Selection | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Bone Marrow Transplantation | Vincristine - administration & dosage | Female | Daunorubicin - administration & dosage | Randomized Controlled Trials as Topic - statistics & numerical data | Dexamethasone - administration & dosage | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cranial Irradiation | Remission Induction | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Thioguanine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Methotrexate - administration & dosage | Research Design | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95
by Hinze, L and Möricke, A and Zimmermann, M and Junk, S and Cario, G and Dagdan, E and Kratz, C.P and Conter, V and Schrappe, M and Stanulla, M
Leukemia, ISSN 0887-6924, 08/2017, Volume 31, Issue 8, pp. 1840 - 1842
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Humans | Mercaptopurine - administration & dosage | Child, Preschool | Treatment Outcome | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Ikaros Transcription Factor - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Gene Deletion | Adolescent | Vincristine - administration & dosage | Methotrexate - administration & dosage | Child | Daunorubicin - administration & dosage | Dexamethasone | Acute lymphatic leukemia | Children | Lymphatic leukemia | Vincristine | Leukemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial
by Mattano, Leonard A, Prof and Devidas, Meenakshi, PhD and Nachman, James B, Prof and Sather, Harland N, PhD and Hunger, Stephen P, Prof and Steinherz, Peter G, Prof and Gaynon, Paul S, Prof and Seibel, Nita L, MD and on behalf of the Children's Oncology Group and Children's Oncology Grp and Children's Oncology Group
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 906 - 915
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Osteonecrosis - epidemiology | Humans | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Incidence | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Child | Daunorubicin - administration & dosage | Osteonecrosis - diagnosis | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Survival Rate | Treatment Outcome | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Sex Factors | Sex Distribution | Methotrexate - administration & dosage | Osteonecrosis - chemically induced | Osteonecrosis - prevention & control | Cohort Studies | Pediatrics | Hunger | Dexamethasone | Bones | Public health | Necrosis | Steroids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Long-term results of the risk-adapted treatment for childhood B-cell acute lymphoblastic leukemia: Report from the Japan association of childhood leukemia study ALL-97 trial
by Horibe, Keizo and Yumura-Yagi, Keiko and Kudoh, Tooru and Nishimura, Shinichiro and Oda, Megumi and Yoshida, Makoto and Komada, Yoshihiro and Hara, Junichi and Tawa, Akio and Usami, Ikuya and Tanizawa, Akihiko and Kato, Koji and Kobayashi, Ryoji and Matsuo, Keitaro and Hori, Hiroki and Japan Assoc Childhood Leukemia Stu and Japan Association of Childhood Leukemia Study (JACLS), Japan
Journal of pediatric hematology/oncology, ISSN 1077-4114, 2017, Volume 39, Issue 2, pp. 81 - 89
clinical trial | childhood | acute lymphoblastic leukemia | Pediatrics | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Japan - epidemiology | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Risk | Consolidation Chemotherapy | Hydrocortisone - administration & dosage | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Doxorubicin - analogs & derivatives | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Daunorubicin - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Mercaptopurine - administration & dosage | Survival Rate | Treatment Outcome | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - radiotherapy | Cranial Irradiation | Remission Induction | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Asparaginase - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Doxorubicin - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
by Lancet, Jeffrey E and Cortes, Jorge E and Hogge, Donna E and Tallman, Martin S and Kovacsovics, Tibor J and Damon, Lloyd E and Komrokji, Rami and Solomon, Scott R and Kolitz, Jonathan E and Cooper, Maureen and Yeager, Andrew M and Louie, Arthur C and Feldman, Eric J
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Life Sciences & Biomedicine | Hematology | Science & Technology | Daunorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cytarabine - adverse effects | Cytarabine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Liposomes | Daunorubicin - administration & dosage | Index Medicus | Abridged Index Medicus | 33 | 8 | Clinical Trials and Observations | 29
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy
by Xiao, Haihua and Li, Wenliang and Qi, Ruogu and Yan, Lesan and Wang, Rui and Liu, Shi and Zheng, Yonghui and Xie, Zhigang and Huang, Yubin and Jing, Xiabin
Journal of controlled release, ISSN 0168-3659, 11/2012, Volume 163, Issue 3, pp. 304 - 314
Drug delivery | Daunorubicin | Oxaliplatin | Combination chemotherapy | Polymer conjugates | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Prodrugs - administration & dosage | Cell Survival - drug effects | Polymers - administration & dosage | Organoplatinum Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Micelles | Cell Line, Tumor | Drug Carriers - administration & dosage | Antineoplastic Agents - administration & dosage | Daunorubicin - administration & dosage | Drugs | Care and treatment | Drug delivery systems | Oxalic acid | Drug therapy, Combination | Polymer industry | Polymers | Cancer | Vehicles | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights